Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Depression*/epidemiology ; Depression*/etiology ; Anxiety*/epidemiology ; Anxiety*/etiology ; Severity of Illness Index*; Humans ; Female ; Male ; Middle Aged ; Adult ; Italy/epidemiology ; Prevalence ; Aged ; Fatty Liver/epidemiology ; Fatty Liver/psychology ; Fatty Liver/etiology ; Cross-Sectional Studies

Purpose: We aimed to evaluate the prevalence of anxiety and depression traits in Italian patients with metabolic dysfunction-associated steatotic liver disease (MASLD), and the possible relation with the severity of liver disease.
Methods: Demographic, anthropometric, clinical and laboratory parameters were collected in patients referred to a metabolic unit for a comprehensive evaluation of possible liver disease. Hepatic steatosis and fibrosis were evaluated by surrogate biomarkers. Imaging (controlled attenuation parameter-CAP and vibration-controlled transient elastography-VCTE). Beck depression inventory (BDI) and state-trait anxiety inventory-Y (STAI-Y) were used to define depressive/anxiety states; calorie intake and lifestyle were self-assessed by questionnaires.
Results: The whole sample comprised 286 patients (61.9% females; mean age 52.0 years; BMI, 34.6 kg/m ² ); 223 fulfilled MASLD criteria. BDI and trait anxiety scores were lower in the MASLD cohort, and the prevalence of both moderate/severe depression and severe trait anxiety was reduced compared with non-MASLD cases, despite VCTE-diagnosed fibrosis F3-F4 present in over 15% of cases. However, after correction for demographic and anthropometric confounders, MASLD was not associated with a lower risk of moderate/severe depression or severe anxiety trait (odds ratio, 0.34; 95% confidence interval, 0.12-1.01 and 0.79, 0.27-2.34). Additional adjustment for the severity of fibrosis did not change the results. No differences in state anxiety were observed.
Conclusion: The risk of anxiety and depression in MASLD is not different from that generated by diabetes and obesity per se. MASLD patients do not perceive liver disease as a specific source of psychological distress, possibly as a consequence of the unawareness of progressive liver disease.
(© 2024. The Author(s).)

J Affect Disord. 2023 May 15;329:184-191. (PMID: 36841305)
Hepatology. 2023 Apr 1;77(4):1335-1347. (PMID: 36626630)
Nutrients. 2023 Dec 26;16(1):. (PMID: 38201910)
Acta Psychiatr Scand. 1995 Dec;92(6):460-3. (PMID: 8837974)
J Hepatol. 2018 Dec;69(6):1349-1356. (PMID: 30142427)
Hepatol Int. 2020 Jul;14(4):556-566. (PMID: 32300995)
Hepatology. 2023 Dec 1;78(6):1966-1986. (PMID: 37363821)
Nutr Metab Cardiovasc Dis. 2022 Jan;32(1):1-16. (PMID: 34924246)
JAMA. 2023 Oct 10;330(14):1370-1380. (PMID: 37815563)
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. (PMID: 34707258)
JHEP Rep. 2021 Sep 17;3(5):100322. (PMID: 34693236)
Ann Intern Med. 2002 Jul 2;137(1):1-10. (PMID: 12093239)
Sci Rep. 2018 Feb 12;8(1):2861. (PMID: 29434331)
World J Hepatol. 2022 Mar 27;14(3):612-622. (PMID: 35582293)
JHEP Rep. 2021 Jan 21;3(2):100234. (PMID: 33733078)
Neurosci Biobehav Rev. 2015 May;52:89-104. (PMID: 25579847)
Lancet. 2005 Sep 24-30;366(9491):1059-62. (PMID: 16182882)
Front Med (Lausanne). 2022 Oct 06;9:985803. (PMID: 36275825)
Hepatol Commun. 2020 Jun 22;4(9):1293-1301. (PMID: 32923833)
J Hepatol. 2023 Sep;79(3):618-634. (PMID: 37353401)
Psychosom Med. 1997 Jan-Feb;59(1):24-31. (PMID: 9021863)
Diabetes Care. 2008 Dec;31(12):2398-403. (PMID: 19033420)
J Hepatol. 2016 Jun;64(6):1388-402. (PMID: 27062661)
Front Med (Lausanne). 2021 Jan 18;7:585618. (PMID: 33537324)
Hepatology. 2007 Jul;46(1):32-6. (PMID: 17567829)
J Pers Assess. 1984 Feb;48(1):95-7. (PMID: 6707862)
Transpl Int. 2018 Dec;31(12):1293-1317. (PMID: 30259574)
J Gastroenterol Hepatol. 2015 Jun;30(6):1009-14. (PMID: 25619308)
Obesity (Silver Spring). 2020 Nov;28(11):2064-2072. (PMID: 33022115)
Obes Rev. 2023 Jul;24(7):e13566. (PMID: 37062534)
J Am Diet Assoc. 2011 Nov;111(11):1712-9. (PMID: 22027054)
J Hepatol. 2018 Oct;69(4):896-904. (PMID: 29886156)
Eur Eat Disord Rev. 2009 Jan;17(1):68-78. (PMID: 18729132)
Aging Ment Health. 2022 Jan;26(1):13-25. (PMID: 33300393)
Neurosci Biobehav Rev. 2015 Feb;49:125-34. (PMID: 25530255)
JAMA Psychiatry. 2017 May 1;74(5):465-475. (PMID: 28297020)
J Psychosom Res. 2023 May;168:111216. (PMID: 36913766)
BMC Gastroenterol. 2006 Nov 02;6:33. (PMID: 17081293)
J Hepatol. 2015 Jul;63(1):237-64. (PMID: 25911335)
Gastroenterology. 2019 May;156(6):1717-1730. (PMID: 30689971)
Eat Weight Disord. 2023 Dec 6;28(1):100. (PMID: 38055131)
Hepatology. 2023 May 1;77(5):1797-1835. (PMID: 36727674)
Front Med (Lausanne). 2021 Jun 30;8:691696. (PMID: 34277666)
Liver Transpl. 2020 Jan;26(1):141-159. (PMID: 31610081)

Keywords: Biomarkers; Distress; Imaging; Liver fibrosis; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Vibration-controlled transient elastography

Date Created: 20240429 Date Completed: 20240816 Latest Revision: 20240819

20240819

PMC11329404

10.1007/s00592-024-02287-0

38684539